This work is licensed under a Creative Commons Attribution 4.0 International License.
B1-Gln
General Information
DRACP ID DRACP00525
Peptide Name B1-Gln
Sequence VKRFKKFFRKLKKQV
Sequence Length 15
UniProt ID Not available
PubChem CID Not available
Origin Cathelicidin-BF15 C-terminal amidated derivative B3
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| MCF-7 | Invasive breast carcinoma of no special type | Carcinoma | IC50=14.5 µM | MTT assay | 48h | 1 |
| K562 | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia | Leukemia | IC50=16.2 µM | MTT assay | 48h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity GES-1: IC50=102.3 µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antimicrobial
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C96H162N28O17
Absent amino acids ACDEGHIMNPSTWY
Common amino acids K
Mass 223040
Pl 12.58
Basic residues 8
Acidic residues 0
Hydrophobic residues 6
Net charge 8
Boman Index -4674
Hydrophobicity -102
Aliphatic Index 64.67
Half Life
Mammalian: 100 hour
Yeast: >20 hour
E.coli: >10 hour
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 0
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 25462264
Title Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities
Doi 10.1016/j.ejmech.2014.10.072
Year 2015
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.